After discussing lifestyle modifications with the patient who is hypertensive, the nurse will reinforce teaching after the patient makes which statement?

Atenolol (Tenormin) is a beta-adrenergic blocker that decreases heart rate, cardiac output, and renin release, while doxazosin (Cardura) is an alpha-adrenergic blocker that causes vasodilation by relaxing vascular smooth muscle. Combining these two antihypertensive agents targets different mechanisms involved in blood pressure regulation, allowing for synergistic blood pressure reduction while minimizing side effects associated with higher doses of a single medication.

Rationale for correct answer:

B. Lower doses of both drugs may be given with fewer adverse effects.
Combination therapy allows each drug to complement the other’s mechanism of action—atenolol reduces cardiac workload and renin secretion, while doxazosin reduces peripheral vascular resistance. This dual approach enables the use of lower doses of both drugs, enhancing efficacy and reducing the risk of dose-related adverse effects such as bradycardia (from beta blockers) or postural hypotension (from alpha blockers).

Rationales for incorrect answers:

A. The blood pressure will decrease faster.
The goal of combination therapy is safe and sustained blood pressure control, not a rapid decrease. A sudden drop in BP can lead to hypotension, dizziness, or syncope, especially in older adults.

C. There is less daily medication dosing.
Combination therapy often involves multiple doses or separate tablets, not necessarily fewer doses. The purpose is enhanced control, not dosing convenience.

D. Combination therapy will treat the patient’s other medical conditions.
Although atenolol may help with cardiac conditions like angina, combination therapy in this context is specifically aimed at improving blood pressure control, not managing unrelated diseases.

Take-home points:
• Combining antihypertensive drugs with different mechanisms enhances blood pressure control and limits side effects.
• Lower doses of each drug in combination therapy improve tolerability and adherence.
• The goal is balanced, sustained blood pressure reduction, not rapid or multi-condition treatment.

The initial pharmacologic management of hypertension typically involves agents that target different mechanisms controlling blood pressure, such as fluid volume, vascular resistance, and cardiac output. Evidence-based guidelines recommend beginning therapy with drugs from the following four classes: diuretics, ACE inhibitors, angiotensin II receptor blockers (ARBs), and calcium channel blockers (CCBs). These medications effectively reduce blood pressure, decrease cardiovascular risk, and are well-tolerated for long-term therapy.

Rationale for correct answers:

A. Diuretics
Thiazide-type diuretics (e.g., hydrochlorothiazide) are often the first-line agents for hypertension. They lower blood pressure by reducing blood volume through sodium and water excretion and by decreasing peripheral vascular resistance. They are particularly effective in older adults and clients with salt-sensitive hypertension.

D. Angiotensin II receptor blockers (ARBs)
ARBs (e.g., losartan, valsartan) block the binding of angiotensin II to its receptors, leading to vasodilation and reduced aldosterone-mediated sodium retention. They are often used when clients cannot tolerate ACE inhibitors due to cough or angioedema.

E. Calcium channel blockers (CCBs)
CCBs (e.g., amlodipine, diltiazem) lower blood pressure by inhibiting calcium influx into vascular smooth muscle and cardiac cells, causing arterial relaxation and vasodilation. They are particularly effective in African American clients and those with isolated systolic hypertension.

F. ACE inhibitors
ACE inhibitors (e.g., lisinopril, captopril) inhibit the conversion of angiotensin I to angiotensin II, leading to vasodilation, reduced aldosterone secretion, and decreased afterload. They are especially beneficial for clients with diabetes or chronic kidney disease due to their renal-protective effects.

Rationales for incorrect answers:

B. Beta blockers
Although beta blockers (e.g., propranolol, metoprolol) can lower blood pressure, they are no longer considered first-line therapy for uncomplicated hypertension. They are more commonly used when there are coexisting conditions such as heart failure, post-MI, or arrhythmias.

C. Aldosterone receptor antagonist
These agents (e.g., spironolactone, eplerenone) are not first-line drugs but are used as add-on therapy in resistant hypertension or when hyperaldosteronism is suspected.

G. Direct renin inhibitors
Aliskiren inhibits renin activity and decreases angiotensin II production but is not typically first-line due to limited long-term outcome data and potential for adverse renal effects when combined with ACE inhibitors or ARBs.

H. Alpha-1 adrenergic blockers
These medications (e.g., doxazosin, prazosin) are used as adjuncts, mainly in clients with benign prostatic hyperplasia (BPH). They are not preferred as initial therapy because of risks of orthostatic hypotension.

Take-home points:
• First-line antihypertensive agents include diuretics, ACE inhibitors, ARBs, and calcium channel blockers.
• Combination therapy is often required to achieve target blood pressure control.
• Drug selection should be individualized based on comorbidities, age, and drug tolerance